Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3674763 | 1.00 | KMT2A (0.39) | KMT2ATSHRHSD17B10MAPTCTSB | |
| SCHEMBL3680130 | 1.00 | KMT2A (0.39) | KMT2ATSHRHSD17B10MAPTCTSB | |
| SCHEMBL3680128 | 1.00 | KMT2A (0.39) | KMT2ATSHRHSD17B10MAPTCTSB | |
| SCHEMBL16694657 | 0.78 | KMT2A (0.39) | KMT2ATSHRHSD17B10CTSBLMNA | |
| SCHEMBL27770082 | 0.75 | KMT2A (0.40) | KMT2ATSHRHSD17B10CTSBLMNA | |
| SCHEMBL16695057 | 0.73 | KMT2A (0.35) | KMT2ATSHRHSD17B10MAPTCTSB | |
| SCHEMBL2353175 | 0.71 | KMT2A (0.45) | KMT2ATSHRHSD17B10CTSBLMNA | |
| SCHEMBL29790848 | 0.71 | GABRA1 (0.44) | MAPTLMNAGABRA1GABRB2TP53 | |
| SCHEMBL2340745 | 0.71 | GABRA1 (0.44) | MAPTLMNAGABRA1GABRB2TP53 | |
| SCHEMBL3676533 | 0.70 | CA1 (0.43) | TSHRLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309779-B2 | Ethylene oligomerization catalyst systems having enhanced selectivity | SK INNOVATION CO., LTD. (KR) | 2012-11-13 | — | — | US | disclosed |
| US-20100145124-A1 | ETHEYENE OLIGOMERIZA CATALYST SYSTEMS HAVING ENEHANCED SELECTIVITY | SK INNOVATION CO., LTD. (KR) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145124-A1 | ETHEYENE OLIGOMERIZA CATALYST SYSTEMS HAVING ENEHANCED SELECTIVITY | CBR3, ESR2, ESR1 | KMT2A 2536/4885TSHR 517/4885HSD17B10 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.